ASH 2022 Conference Coverage
ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition With Sabatolimab Added to HMAs in Adult Patients With Higher-Risk MDS
By
ASH 2022 Conference Coverage
FEATURING
Amer Zeidan
By
ASH 2022 Conference Coverage
FEATURING
Amer Zeidan
Login to view comments.
Click here to Login
